as 12-18-2024 2:35pm EST
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Founded: | 1979 | Country: | United States |
Employees: | N/A | City: | JUPITER |
Market Cap: | 31.5M | IPO Year: | 2004 |
Target Price: | $6.00 | AVG Volume (30 days): | 74.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.22 | EPS Growth: | N/A |
52 Week Low/High: | $0.93 - $2.67 | Next Earning Date: | 11-12-2024 |
Revenue: | $3,364,548 | Revenue Growth: | 13.82% |
Revenue Growth (this year): | 51.3% | Revenue Growth (next year): | 73.26% |
DYAI Breaking Stock News: Dive into DYAI Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
Zacks Small Cap Research
a month ago
GuruFocus.com
a month ago
GlobeNewswire
a month ago
GuruFocus.com
a month ago
GlobeNewswire
a month ago
The information presented on this page, "DYAI Dyadic International Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.